Of these, 3 patients in Group A, 4 patients in Group B, 4 patients in Group C, and 7 patients in group D were found to be ineligible after randomisation (10 patients were taking aspirin and/or atorvastatin before randomisation, 4 patients had thrombocytopenia, 2 patients had coagulopathy, 1 patient had raised baseline CPK, and 1 patient had raised baseline liver enzymes). The gene discussed is PIK3C2A; the disease is Thrombocytopenia.